Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients.
Clin Transplant
December 2024
Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline-recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV).
Methods: Adults undergoing LTX between January 1, 2021, and July 30, 2022 at our institution who were converted from VGC to LTV for PPX were evaluated.
Interventions for BK virus infection in kidney transplant recipients.
Cochrane Database Syst Rev
October 2024
Department of Renal Medicine, The Canberra Hospital, Canberra, Australia.
Article Synopsis
- BK virus-associated nephropathy (BKVAN) is a complication in kidney transplantation due to BK virus infection, requiring careful screening and management primarily through reduced immunosuppression, as no effective antiviral therapy exists.
- This review evaluated the effectiveness and risks of various interventions for treating or preventing BKVAN among kidney transplant recipients, including examining randomized controlled trials and cohort studies.
- The review included 12 RCTs with a total of 2,669 participants, analyzing data through rigorous methods to assess the quality and effectiveness of these interventions.
Determining Effectiveness of "Off-Label Therapies" for Multiple Sclerosis in a Real-World Setting.
Ann Indian Acad Neurol
May 2024
Center for Advanced Neurological Research, Nitte University, Mangalore, Karnataka, India.
Objective: To determine the factors, if any, that are associated with the efficacy of "off-label therapies" (OLTs) for multiple sclerosis (MS).
Methods: Consecutive patients (N = 174) with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) with relapses, on OLTs with a generic formulation of azathioprine, mycophenolate mofetil, or rituximab biosimilar for ≥2 years were included. Annualized relapse rate (ARR) and expanded disability status score (EDSS) 1 year before and ≥2 years after starting OLTs were recorded.
Background: Diarrhea is a common adverse effect of mycophenolate treatment in renal transplant recipients. In patients with mycophenolate-induced diarrhea, one option is to switch to mycophenolate to azathioprine. In this study, we aimed to define the safety and efficacy of switching from mycophenolate to azathioprine for mycophenolate-related diarrhea in renal transplant recipients.
View Article and Find Full Text PDFSimultaneous Monitoring of Azathioprine Metabolites in Erythrocytes of Crohn's Disease Patients by HPLC-UV.
J Chromatogr Sci
July 2022
Laboratory of Clinical and Experimental Pharmacology, Department of Pharmacology, Federal University of Juiz de Fora, José Lourenço Kelmer, s/n°, 36360-900, Juiz de Fora, Minas Gerais, Brazil.
The conversion of azathioprine (AZA) to active 6-thioguanine nucleotides (6-TGN) is essential for its clinical efficacy; however, another metabolite formed, 6-methylmercaptopurine (6-MMP), is related to hepatotoxicity. Blood samples were collected from 37 patients under AZA's treatment, and a new HPLC-UV method was validated and applied for simultaneous quantification of 6-TGN and 6-MMP in erythrocytes of Crohn's disease (CD) patients. The concentration of 6-TGN and 6-MMP found ranged from 4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!